

## Chiltern and Medidata Mark 10-Year Anniversary Milestone in Bringing Cloud-based Technology to Clinical Development

WILMINGTON, N.C. & NEW YORK--(BUSINESS WIRE)-- [Medidata](#) (NASDAQ:MDSO), the leading global provider of cloud-based technology and data analytics for clinical research, and [Chiltern](#), a leading global contract research organization (CRO), today announced an anniversary milestone in their strategic partnership.

The two organizations have been working together for 10 years to deliver world-class clinical development services to Chiltern's broad customer base via the [Medidata Clinical Cloud](#)<sup>®</sup>.

Known for its collaborative approach designed around its clients, Chiltern offers comprehensive programs and functional service provisions (FSP) to the global pharmaceutical, biotechnology and device markets. The organization has deep experience in oncology, dermatology, endocrine and metabolic, gastroenterology, respiratory, ophthalmology and neuroscience, among others — enabling its 4,300+ staff to fold unique therapeutic expertise into its wide range of clinical development and data and analytics services.

In its 35 years of operations, Chiltern has spent the last decade bolstering its R&D and scientific expertise with Medidata's unified technology platform. Chiltern joined Medidata's Partner Program in 2007, when it became accredited in Medidata's industry-leading electronic data capture, management and reporting tool, [Medidata Rave](#)<sup>®</sup>. Since then, Chiltern has continued to increase its use of the Medidata platform, further enhancing its innovative research programs with accreditations across Medidata's portfolio of integrated solutions, including: [Medidata Coder](#)<sup>®</sup>, [Medidata Balance](#)<sup>®</sup>, [Medidata TSDV](#), [Safety Gateway](#) and [Medidata Patient Cloud](#)<sup>®</sup>. Today, Chiltern has over 130 Rave-certified builders on staff and has built over 750 studies on the Medidata platform.

"As the global life sciences landscape continues to evolve, it's important that Chiltern aligns itself with innovative technology partners that have the agility, scale and insight to meet the most rigorous aspects of clinical development today—from real-time analytics to risk-based monitoring, biometrics and pharmacovigilance. Medidata is one of those partners," said Mark Penniston, Chiltern's executive vice president, clinical analytics, and general manager. "Leveraging Medidata's end-to-end platform has enabled us to effectively allocate study resources, standardize data and seamlessly integrate clinical and operational information across our customers' global R&D programs. We've spent the past 10 years helping our customers drive clinical success on the Medidata Clinical Cloud, and we look forward to many more."

"Medidata's extensive partnership with Chiltern reflects our shared commitment to marrying cutting-edge technology, data-driven processes and scientific excellence to develop better therapies for patients," said Mike Capone, Medidata chief operating officer. "Chiltern is a collaborative organization driving personalized R&D programs for its global customers, and as Chiltern's cloud platform of choice, we're proud to provide them with the tools and techniques needed to ensure clinical data quality, study accuracy and operational speed. We look forward to further strengthening our partnership and celebrating the continued success of our customers' medical advancements together."

Chiltern was the winner of Medidata's inaugural "[Architect of Hope](#)" Award in 2016, an award in recognition of the CRO's successful partnership with a major biopharmaceutical company. The organization will continue to use Medidata's study conduct solutions and patient engagement tools in a number of its upcoming studies, as well as tap into Medidata's latest mobile health (mHealth) offering, [Medidata Enroll](#), for electronic informed consent.

*Attending the DIA 2017 Annual Meeting in Chicago, June 18-22? Be sure to visit Medidata at booth 1318 and Chiltern at booth 1807 for more on our respective clinical research solutions and services.*

### Connect with Medidata

- | Read our blog, [Geeks Talk Clinical](#)
- | Tweet this: [.@Chiltern\\_CRO & @Medidata celebrate 10 yrs of bringing #cloud #tech & #data analytics to #clinicalresearch: http://ow.ly/vSLI30cx4zV](#)
- | Follow us on Twitter: [@Medidata](#)
- | Find us on [LinkedIn](#)

## About Chiltern

[Chiltern](#), a global contract research organization, is a leading provider of clinical services and solutions in a variety of therapeutic areas with engagement models for biopharmaceutical and medical device industries. Chiltern's team of more than 4,300, located across 47 countries, provides comprehensive Clinical Development, Medical & Scientific Affairs, Data & Analysis, Pharmacovigilance and Strategic Regulatory services using a collaborative approach for more efficient clinical trials. Visit [Chiltern.com](#) to learn more about how Chiltern is Designed Around You<sup>®</sup>.

## About Medidata

[Medidata](#) is reinventing global drug and medical device development by creating the industry's leading cloud-based solutions for clinical research. Through our advanced applications and intelligent data analytics, Medidata helps advance the scientific goals of life sciences customers worldwide, including over 850 global pharmaceutical companies, biotech, diagnostic and device firms, leading academic medical centers, and contract research organizations.

The Medidata Clinical Cloud<sup>®</sup> brings a new level of quality and efficiency to clinical trials that empower our customers to make more informed decisions earlier and faster. Our unparalleled clinical trial data assets provide deep insights that pave the way for future growth. The Medidata Clinical Cloud is the primary technology solution powering clinical trials for 18 of the world's top 25 global pharmaceutical companies and is used by 18 of the top 25 medical device developers—from study design and planning through execution, management and reporting.

View source version on [businesswire.com](#): <http://www.businesswire.com/news/home/20170613005375/en/>

### **Medidata:**

#### ***Investor:***

Medidata Solutions  
Anthony D'Amico, +1 732-767-4331  
[adamico@mdsol.com](mailto:adamico@mdsol.com)

or

#### ***Media:***

Medidata Solutions  
Erik Snider, +1 646-362-2997  
[esnider@mdsol.com](mailto:esnider@mdsol.com)

or

### **Chiltern:**

#### ***Media:***

SCORR Marketing  
Lea Studer, 308-237-5567  
[lea@scorrmktg.com](mailto:lea@scorrmktg.com)

Source: Medidata

News Provided by Acquire Media